Cell and Gene Therapy Services Market Size and Share Analysis - Growth Trends and Forecasts (2025-2032)

Market Size and Trends

The Cell and Gene Therapy Services market is estimated to be valued at USD 18.6 billion in 2024 and is expected to reach USD 52.4 billion by 2031, growing at a compound annual growth rate (CAGR) of 15.3% from 2024 to 2031. This rapid expansion is driven by increasing investments in advanced therapies, rising prevalence of chronic diseases, and technological advancements that enhance the development and delivery of personalized treatments worldwide.

A significant market trend is the growing adoption of automated and scalable manufacturing solutions, which streamline cell and gene therapy production, reducing costs and improving accessibility. Furthermore, strategic collaborations between biopharmaceutical companies and research institutions are accelerating innovation cycles. Additionally, regulatory bodies are progressively adapting frameworks to accommodate novel therapies, encouraging faster approvals and wider commercialization, ultimately fueling sustained market growth and expanded patient access.

Segmental Analysis:

By Therapy Type: Dominance of Autologous Cell Therapy Driven by Personalized Treatment Advancements

In terms of By Therapy Type, Autologous Cell Therapy contributes the highest share of the market owing to its personalized approach and proven safety profile. This segment benefits from the therapy's ability to use a patient's own cells, reducing the risk of immune rejection and adverse reactions compared to allogeneic options. The focus on personalized medicine, particularly in oncology and regenerative therapies, has accelerated the adoption of autologous treatments, as these therapies can be tailored precisely to the genetic and biological makeup of individual patients. Furthermore, technological advancements in cell processing, culture techniques, and genetic modification have enhanced the efficacy and scalability of autologous cell therapies, increasing their appeal among healthcare providers and patients alike. Regulatory pathways have also become more adaptive, supporting clinical trials and faster approvals of autologous therapies, which propels further investment and innovation in this segment. The continued exploration of diseases like hematological malignancies and rare genetic disorders expands the application scope of autologous treatments, maintaining their leadership in the therapy landscape.

By Service Type: Manufacturing as the Backbone of Cell and Gene Therapy Growth

By Service Type, Manufacturing commands the highest share of the Cell and Gene Therapy Services market, driven largely by the critical need for robust, scalable, and compliant production processes. The complexity of cell and gene therapies requires highly specialized manufacturing protocols, including stringent quality control, aseptic processing, and advanced bioreactor technologies, which fuel demand for manufacturing services. As more therapies progress from clinical trials to commercialization, the industry faces heightened pressure to optimize manufacturing capacity, reduce production costs, and improve turnaround times to meet growing patient needs. Additionally, the personalized nature of many therapies, particularly autologous, demands flexible and agile manufacturing setups capable of handling small batch sizes while ensuring consistency and safety. Partnerships between therapy developers and contract manufacturing organizations are also expanding, as these manufacturers offer expertise, infrastructure, and regulatory compliance that many developers lack internally. Investments in automation, digital tracking, and process analytical technologies further enhance manufacturing efficiency, solidifying this segment's central role in advancing the cell and gene therapy market.

By End-User: Pharmaceutical & Biotechnology Companies Leading Innovation and Commercialization

By End-User, Pharmaceutical & Biotechnology Companies hold the dominant share in the Cell and Gene Therapy Services market, propelled by their substantial investments in research, development, and commercialization efforts. These companies drive demand through large-scale clinical trials, pipeline expansion, and ongoing efforts to bring novel therapies to market. Their involvement is critical for translating early-stage research into viable therapies, supported by deep expertise in regulatory affairs, marketing, and distribution. The competitive landscape within pharmaceutical and biotechnology sectors motivates continuous innovation, pushing the advancement of new modalities and platform technologies in cell and gene therapy. Moreover, strategic collaborations and acquisitions within the industry enable pharmaceutical and biotech firms to integrate specialized service providers, streamlining development phases from laboratory bench to patient bedside. This end-user segment also actively pursues improvements in supply chain management and manufacturing scalability, recognizing that these factors directly impact commercial success. Their role as primary customers for service providers across manufacturing, testing, and logistics reinforces their position as key growth drivers in the broader market ecosystem.

Regional Insights:

Dominating Region: North America

In North America, the dominance in the Cell and Gene Therapy Services market is driven by a robust ecosystem of research institutions, a mature healthcare infrastructure, and substantial government support for advanced biotechnologies. The United States, in particular, benefits from strong regulatory frameworks such as the FDA's regenerative medicine policies, which facilitate faster clinical approvals and commercialization. Additionally, extensive collaborations between industry leaders, academic centers, and contract development and manufacturing organizations (CDMOs) fuel innovation and production capacity. Major companies like Novartis, Kite Pharma (a Gilead company), and Thermo Fisher Scientific have been pivotal in advancing cell and gene therapy manufacturing and development, providing integrated services ranging from vector production to clinical trial support. The presence of numerous biotechnology hubs and a favorable investment climate further reinforce North America's leading position in this market.

Fastest-Growing Region: Asia Pacific

Meanwhile, the Asia Pacific exhibits the fastest growth in the Cell and Gene Therapy Services market, attributed to increasing government initiatives to boost biotechnology infrastructure, expanding healthcare expenditure, and rising prevalence of chronic diseases that create demand for advanced therapies. Countries such as China, Japan, and South Korea are rapidly developing regulatory frameworks and manufacturing capabilities to catch up with western markets. The region's cost-effective clinical trial environments and manufacturing facilities attract multinational companies looking to expand operations and lower production costs. Notable firms such as WuXi AppTec, Samsung Biologics, and Takara Bio are expanding their cell and gene therapy service offerings, spanning from early-stage development to commercial manufacturing, and significantly shaping the competitive landscape.

Cell and Gene Therapy Services Market Outlook for Key Countries

United States

The United States' market is propelled by leading biotechnology companies like Novartis and Gilead Sciences investing heavily in next-generation CAR-T therapies and gene-editing platforms. Advanced academic research centers foster continuous innovation, while government initiatives such as the NIH's regenerative medicine programs provide strong backing. The country's well-established CDMO network, including companies like Lonza and Thermo Fisher Scientific, ensures seamless service integration, facilitating rapid product development and scaling.

China

China's rapidly evolving regulatory standards and increased funding for biotechnology research have turned it into a hotspot for cell and gene therapy development. Companies such as WuXi AppTec and Legend Biotech are significant contributors, offering end-to-end services that attract both domestic and international clients. The government's focus on self-reliance in healthcare technologies combined with expanded biomanufacturing infrastructure provides a strong foundation for continued market expansion.

Germany

Germany, representing a key European market, benefits from a strong pharmaceutical and biotech base, and favorable government policies promoting advanced therapeutics. Established players like BioNTech and Miltenyi Biotec are pioneering innovations in gene editing and cell processing technologies. High-quality research institutions combined with supportive reimbursement frameworks allow Germany to maintain a competitive edge in Europe's cell and gene therapy service landscape.

Japan

Japan's market is distinguished by its early adoption of regenerative medicine laws and expedited approval processes for cell and gene therapies. With companies such as Takara Bio and CellSeed leading in manufacturing and clinical development, the country fosters a thriving environment for advanced therapies. Additionally, Japan's integration of robotics and automation in manufacturing enhances production efficiencies, supporting market growth.

South Korea

South Korea's rapidly growing market is fueled by government incentives, strong investment in biotech infrastructure, and a skilled workforce specializing in cell therapy research. Samsung Biologics and SillaJen are key players driving innovation and expanding manufacturing capacity tailored to gene therapies. The country is also capitalizing on strategic partnerships with global pharmaceutical companies to strengthen its market position and accelerate therapy availability.

Market Report Scope

Market Segmentation

Therapy Type Insights (Revenue, USD, 2020 - 2032)

• Autologous Cell Therapy
• Allogeneic Cell Therapy
• Gene Therapy
• Others

Service Type Insights (Revenue, USD, 2020 - 2032)

• Manufacturing
• Analytical Testing
• Logistics & Supply Chain
• Consulting
• Others

End-user Insights (Revenue, USD, 2020 - 2032)

• Pharmaceutical & Biotechnology Companies
• Academic Research & Clinical Institutes
• Contract Research Organizations (CROs)
• Others

Regional Insights (Revenue, USD, 2020 - 2032)

• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa

Key Players Insights

• Thermo Fisher Scientific
• Catalent Inc.
• Lonza Group AG
• Novartis AG
• WuXi AppTec
• Samsung Biologics
• Fujifilm Diosynth Biotechnologies
• GE Healthcare
• Oxford Biomedica plc
• Brammer Bio
• Charles River Laboratories
• Celyad Oncology
• Patheon (part of Thermo Fisher)
• Cobra Biologics
• Sorrento Therapeutics